Cogent Biosciences Inc (COGT)

$8.79

+0.43

(+5.14%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Cogent Biosciences Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 76.2% return, outperforming this stock by 106.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.2% return, outperforming this stock by 245.4%

Performance

  • $8.32
    $9.04
    $8.79
    downward going graph

    5.35%

    Downside

    Day's Volatility :7.96%

    Upside

    2.77%

    downward going graph
  • $3.67
    $13.36
    $8.79
    downward going graph

    58.25%

    Downside

    52 Weeks Volatility :72.53%

    Upside

    34.21%

    downward going graph

Returns

PeriodCogent Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
25.34%
0.7%
0.0%
6 Months
52.0%
8.4%
0.0%
1 Year
-30.62%
10.5%
0.0%
3 Years
-10.11%
17.1%
-23.0%

Highlights

Market Capitalization
980.8M
Book Value
$2.09
Earnings Per Share (EPS)
-2.49
Wall Street Target Price
16.7
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-38.43%
Return On Equity TTM
-65.7%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-121.6M
EBITDA
-225.0M
Diluted Eps TTM
-2.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.28
EPS Estimate Next Year
-2.25
EPS Estimate Current Quarter
-0.52
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Cogent Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 89.99%

Current $8.79
Target $16.70

Technicals Summary

Sell

Neutral

Buy

Cogent Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cogent Biosciences Inc
Cogent Biosciences Inc
5.56%
52.0%
-30.62%
-10.11%
249.79%
Moderna, Inc.
Moderna, Inc.
-17.71%
41.64%
11.55%
-39.28%
857.26%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.07%
24.05%
34.11%
95.48%
226.11%
Novo Nordisk A/s
Novo Nordisk A/s
5.19%
37.27%
76.22%
243.21%
449.78%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cogent Biosciences Inc
Cogent Biosciences Inc
NA
NA
NA
-2.28
-0.66
-0.38
NA
2.09
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cogent Biosciences Inc
Cogent Biosciences Inc
Buy
$929.4M
249.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
857.26%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
226.11%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
449.78%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
158.93%
30.3
39.46%

Institutional Holdings

  • Kynam Capital Management, LP

    8.89%
  • BlackRock Inc

    7.07%
  • Vanguard Group Inc

    6.03%
  • TCG Crossover Management, LLC

    5.89%
  • COMMODORE CAPITAL LP

    5.82%
  • FMR Inc

    5.55%

Company Information

unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act

Organization
Cogent Biosciences Inc
Employees
164
CEO
Mr. Andrew R. Robbins M.B.A.
Industry
Health Technology

FAQs